Login to Your Account



Search

Search results

Pharma: Clinic roundup

Merck & Co. Inc. , of Whitehouse Station, N.J., said the data monitoring committee for the Phase II/III EPOCH study testing MK-8931, an oral beta-amyloid precursor protein site-cleaving enzyme, or BACE, inhibitor, in mild to moderate Alzheimer’s ...

BioWorld Today - Staff - 2013-12-11 01:00 - 0 comments - 0 attachments

Pharma: Clinic roundup

Summit Corp. plc, of Oxford, UK, said the first Duchenne Muscular Dystrophy (DMD) patient has been enrolled and dosed in a Phase Ib clinical trial of the oral, small molecule utrophin modulator SMT C1100. (BioWorld-Today-2013-12-10) ...

BioWorld Today - Staff - 2013-12-10 01:00 - 0 comments - 0 attachments

Pharma: Clinic roundup

Shire plc , of London, reported top-line Phase III results with its lifitegrast dry-eye treatment. (BioWorld-Today-2013-12-09) ...

BioWorld Today - Staff - 2013-12-09 01:00 - 0 comments - 0 attachments

Pharma: Clinic roundup

Eli Lilly and Co., of Indianapolis, reported that three Phase III studies of edivoxetine failed to meet the primary objective of superior efficacy in major depressive disorder (MDD) after eight weeks of treatment. When added to a selective serotonin ...

BioWorld Today - Staff - 2013-12-06 01:00 - 0 comments - 0 attachments

Pharma: Clinic Roundup

• Sanofi SA , of Paris, reported full results from the EDITION II study of investigational insulin U300, showing that 23 percent fewer patients experienced night-time low blood sugar compared with Lantus (insulin glargine [rDNA origin] injection). ...

BioWorld Today - Staff - 2013-12-04 01:00 - 0 comments - 0 attachments

Pharma: Clinic Roundup

• Janssen Pharmaceutica NV , of Beerse, Belgium, part of Johnson & Johnson, reported results of the PALMFlexS study. Data showed flexible maintenance dosing with Xeplion (paliperidone palmitate) was associated with a clinically relevant treatme ...

BioWorld Today - Staff - 2013-12-03 01:00 - 0 comments - 0 attachments

Pharma: Clinic Roundup

• A.P. Pharma Inc. , of Redwood City, Calif., reported additional data from a Phase III trial of APF530, for chemotherapy-induced nausea and vomiting. (BioWorld-Today-2012-07-02) ...

BioWorld Today - Staff - 2012-07-02 00:00 - 0 comments - 0 attachments

Pharma: Clinic Roundup

• Galleon Pharmaceuticals Inc. , of Horsham, Pa., said its drug candidate GAL-021 was safe and well tolerated in a Phase I trial in 30 healthy adults. The company is investigating GAL-021 for improving breathing in patients receiving opioids, w ...

BioWorld Today - Staff - 2012-05-08 00:00 - 0 comments - 0 attachments

Pharma: Clinic Roundup

• Pfizer Inc. , of New York, said it entered an agreement with Glaxosmithkline plc , of London, to explore the anticancer efficacy and safety of GSK’s trametinib (GSK1120212) combined with Pfizer’s palbociclib (PD-0332991) in a Phase I/II study ...

BioWorld Today - Staff - 2013-11-22 01:00 - 0 comments - 0 attachments

Pharma: Clinic Roundup

• CSL Ltd. , of King of Prussia, Pa., presented data at the American Heart Association meeting in Dallas showing that CSL112 demonstrated favorable safety and tolerability when administered to patients with stable atherothrombotic disease and showed ...

BioWorld Today - Staff - 2013-11-21 01:00 - 0 comments - 0 attachments